APA (7th ed.) Citation

Pollack, C. V., & Steiner, T. (2017). Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: Interim results from the RE-VERSE ADTM study. Journal of medical economics, 20(5), . https://doi.org/10.1080/13696998.2016.1273229

Chicago Style (17th ed.) Citation

Pollack, Charles V., and Thorsten Steiner. "Healthcare Resource Utilization in Patients Receiving Idarucizumab for Reversal of Dabigatran Anticoagulation Due to Major Bleeding, Urgent Surgery, or Procedural Interventions: Interim Results from the RE-VERSE ADTM Study." Journal of Medical Economics 20, no. 5 (2017). https://doi.org/10.1080/13696998.2016.1273229.

MLA (9th ed.) Citation

Pollack, Charles V., and Thorsten Steiner. "Healthcare Resource Utilization in Patients Receiving Idarucizumab for Reversal of Dabigatran Anticoagulation Due to Major Bleeding, Urgent Surgery, or Procedural Interventions: Interim Results from the RE-VERSE ADTM Study." Journal of Medical Economics, vol. 20, no. 5, 2017, https://doi.org/10.1080/13696998.2016.1273229.